Company overview
Quanta Therapeutics develops oral, allosteric small molecule inhibitors targeting KRAS mutations like G12D and G12V in RAS-driven cancers including pancreatic, colorectal, lung, and endometrial. Their pipeline features Phase 1 candidates QTX3034, QTX3544, and QTX3046, leveraging a proprietary Second Harmonic Generation platform for protein conformational detection. The company advances best-in-class therapies to expand treatment options beyond G12C mutations.
Quanta Therapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include kras inhibitors, quanta therapeutics, ras-driven cancers, allosteric modulators, oncology therapeutics.
Structured facts
- Website
- https://www.quantatx.com
- Markets served
- United States & Americas
- Keywords
- kras inhibitors, quanta therapeutics, ras-driven cancers, allosteric modulators, oncology therapeutics
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What KRAS mutations does Quanta target?
- Quanta targets KRAS G12D and G12V mutations primarily, with multi-KRAS inhibitors like QTX3034 (G12D-preferring) and QTX3544 (G12V-preferring), addressing cancers such as pancreatic, colorectal, lung, and endometrial.
- What is the clinical stage of Quanta's pipeline?
- QTX3034 and QTX3544 are in Phase 1 clinical trials, with QTX3034 advancing to dose expansion in KRAS G12D-mutant cancers based on favorable safety and efficacy data; QTX3046 is also progressing.
- What technology powers Quanta's drug discovery?
- Quanta uses a Second Harmonic Generation (SHG) platform, an optical technology that detects subtle protein conformational changes to identify allosteric modulators of RAS signaling complexes.
Related editorial coverage
- AACR 2026: Myocarditis Risk, KRAS Inhibitors, mRNA Advances
- KRAS Inhibitors for NSCLC: Complete Guide to Latest FDA Approvals 2024
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
